AbbVie Inc. or Protagonist Therapeutics, Inc.: Who Invests More in Innovation?

Innovation Investment: AbbVie Inc. vs. Protagonist Therapeutics, Inc.

In the ever-evolving pharmaceutical landscape, innovation is the lifeblood of progress. Over the past decade, AbbVie Inc. and Protagonist Therapeutics, Inc. have demonstrated contrasting approaches to research and development (R&D) investments. From 2014 to 2023, AbbVie consistently allocated substantial resources to R&D, with an average annual investment of approximately $6.2 billion. This commitment peaked in 2018, with a remarkable 10% of their revenue channeled into innovation.

Conversely, Protagonist Therapeutics, a smaller player, invested an average of $66 million annually in R&D during the same period. Despite their modest scale, Protagonist's R&D spending grew by over 1,500% from 2014 to 2023, reflecting their dedication to innovation.

This data underscores the diverse strategies within the pharmaceutical industry, where both giants and emerging companies strive to push the boundaries of medical science.